EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> Lundbeck offloaded two preclinical programs to AstraZeneca. The deal continues Lundbeck’s push to shed assets that are outside of its area of focus. Statement

> UniQure presented data on its hemophilia B gene therapy program. The data suggest the vector used by uniQure achieves liver transduction in the presence of pre-existing anti-AAV5 neutralizing antibodies. Release 

> 4D Pharma gained clearance to trial a commensal bacteria strain in cancer patients. The trial will look at the immunomodulatory effects of MRx0518 in people with solid tumors. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sensorion raised €8.7 million ($10.2 million). The money will fund the completion of a phase 2 trial of SENS-111 in patients with rare ear disease vestibular neuritis. Release 

> Cellectis gained clearance to increase the dose levels in a phase 1 trial of off-the-shelf CAR-T drug UCART123. The French biotech is also opening another site in a bid to increase the speed of enrollment. Statement 

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.